Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2019 08:00 ET | Source: Krystal Biotech, Inc.

EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa

First EMA PRIME eligibility for Krystal BiotechEligibility based on positive primary analysis of clinical and non clinical data to datePRIME Designation allows for frequent and early interactions with...
March 12, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports 2018 Financial Results and Business Progress

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and...
March 06, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters

New facility expected to meet all clinical and commercial development needs of lead program KB103A second, larger cGMP facility expected to be completed in 2020 to meet all anticipated future pipeline...
March 04, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli

PITTSBURGH, March 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (Krystal) (NASDAQ: KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases,...
March 01, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference

PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
February 22, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

PITTSBURGH, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
January 15, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa

PITTSBURGH, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare...
December 19, 2018 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare...
November 20, 2018 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at Evercore ISI HealthCONx

PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
November 05, 2018 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa ...